Going APOA1 in cancer
Researchers at the University of California, Los Angeles and colleagues have shown that apolipoprotein A-1, the major component of high-density lipoprotein, could have a therapeutic effect in ovarian cancer.1 Resverlogix Corp., a biotech with an apolipoprotein A-1 program in cardiovascular disease, is considering out-licensing options for oncology based on the findings.
Apolipoprotein A-1 (APOA1) is a key component of the reverse cholesterol transport pathway. The lipoprotein removes cholesterol from cells in the periphery and helps shuttle it to the liver, where cholesterol is excreted. Given APOA1's role in cholesterol-related disorders such as atherosclerosis, companies pursuing APOA1 or its mimics in the cardiovascular space include two sets of biotech-pharma partners...